Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

INTRODUCTION: Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)(1–40) and Aβ(1–42) in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement (N Y)
Main Authors: Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2018
Assuntos:
Featured Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258891/
https://ncbi.nlm.nih.gov/pubmed/30511011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.10.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados